coupling of structure-specific in vivo chemical modification to next-generation sequencing is transforming rnA secondary structure studies in living cells. the dominant strategy for detecting in vivo chemical modifications uses reverse transcriptase truncation products, which introduce biases and necessitate population-average assessments of rnA structure. here we present dimethyl sulfate (dms) mutational profiling with sequencing (dms-maPseq), which encodes dms modifications as mismatches using a thermostable group ii intron reverse transcriptase. dms-maPseq yields a high signal-to-noise ratio, can report multiple structural features per molecule, and allows both genome-wide studies and focused in vivo investigations of even low-abundance rnAs. We apply dms-maPseq for the first analysis of rnA structure within an animal tissue and to identify a functional structure involved in noncanonical translation initiation. Additionally, we use dms-maPseq to compare the in vivo structure of premrnAs with their mature isoforms. these applications illustrate dms-maPseq's capacity to dramatically expand in vivo analysis of rnA structure.
coupling of structure-specific in vivo chemical modification to next-generation sequencing is transforming rnA secondary structure studies in living cells. the dominant strategy for detecting in vivo chemical modifications uses reverse transcriptase truncation products, which introduce biases and necessitate population-average assessments of rnA structure. here we present dimethyl sulfate (dms) mutational profiling with sequencing (dms-maPseq), which encodes dms modifications as mismatches using a thermostable group ii intron reverse transcriptase. dms-maPseq yields a high signal-to-noise ratio, can report multiple structural features per molecule, and allows both genome-wide studies and focused in vivo investigations of even low-abundance rnAs. We apply dms-maPseq for the first analysis of rnA structure within an animal tissue and to identify a functional structure involved in noncanonical translation initiation. Additionally, we use dms-maPseq to compare the in vivo structure of premrnAs with their mature isoforms. these applications illustrate dms-maPseq's capacity to dramatically expand in vivo analysis of rnA structure.
RNA is a functionally diverse molecule that both carries genetic information and directly conducts biological processes through its ability to fold into complex secondary and tertiary structures 1 . The discovery of functional RNA structures depends critically on accurate, targeted, and accessible RNA structure determination methods, particularly in vivo. Sequence information alone is generally not sufficient for prediction of RNA structure, but by combining sequence information with experimental structure data at single-nucleotide resolution, one can often obtain an accurate assessment of RNA folding status and discover novel RNA structures [2] [3] [4] .
Existing high-resolution techniques to measure RNA secondary structure are based on structure-specific chemical modification. DMS has emerged as one of the pre-eminent choices for this application. DMS rapidly and specifically modifies unpaired adenines and cytosines in vivo at their Watson-Crick base-pairing positions 5 . Selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE) chemicals are another powerful option for dms-maPseq for genome-wide or targeted rnA structure probing in vivo Meghan Zubradt 1 , Paromita Gupta 2 , Sitara Persad 2 , Alan M Lambowitz 3 , Jonathan S Weissman 1 & Silvi Rouskin 2 chemical RNA structure probing. Because of their distinct mechanisms of modification, DMS and SHAPE report on different and complementary aspects of RNA structure 6, 7 . In early efforts, chemical lesions from either SHAPE or DMS were detected when the reverse transcriptase (RT) enzyme terminated cDNA synthesis upon reaching a modified nucleotide. We and others have coupled the chemical probing of RNA structure to nextgeneration sequencing ( Fig. 1) , allowing for experimental analysis of RNA structure on a global scale in vitro or in vivo 4, [8] [9] [10] [11] (see refs. 12 and 13 for reviews of sequencing-coupled RNA structure techniques). Globally, these experiments have revealed substantial differences in RNA structure in vivo versus in vitro, underscoring the importance of examining RNA structure in its native cellular environment 4, 10 .
Despite important contributions to RNA structure discovery, truncation-based approaches using either DMS or SHAPE have intrinsic limitations that render them unsuitable to address certain biological questions, such as the heterogeneity of RNA structures in vivo. We sought to develop an in vivo and genome-wide approach that would overcome existing limitations in truncation strategies by encoding DMS lesions as mutations instead of as cDNA truncations, as has been recently described for individual or highly abundant RNA targets 7, [14] [15] [16] . Such mutational profiling (MaP) approaches confer several advantages. These advantages include the resolution of enzymatic biases proximal to the informationencoding nucleotide and (most importantly) the analysis of multiple chemical modification sites per molecule, which opens up the possibility of distinguishing heterogeneous RNA structure subpopulations from one another in vivo. In truncation approaches, only a single site of chemical modification can be observed per RNA molecule; thus, the structure signal corresponds to a population average. Additionally, low-abundance RNAs are not conducive to truncation-based RNA structure probing. Specifically, they are poorly sequenced on a genome-wide scale, and input requirements for available low-throughput methods often necessitate in vitro transcription before structure profiling 6, 14, 15, 17 . We reasoned that an in vivo MaP approach would make it possible to perform targeted amplification of low-abundance RNA species while retaining a record of the modification sites.
Here we describe DMS-MaPseq, an RNA structure probing strategy that takes advantage of a high-fidelity and processive thermostable group II reverse transcriptase (TGIRT) enzyme. We apply this technique globally in vivo and for selected RNA species, including low-abundance RNA targets in yeast and human cells, producing the high signal and low background necessary for high data quality. We also highlight a simple RT-PCR approach for targeted amplification and demonstrate RNA experiments inaccessible by previous techniques such as the investigation of isoform-specific RNA structure and the discovery of a functional structure in the low-abundance human FXR2 mRNA. DMS-MaPseq enables a far broader exploration of in vivo RNA structure and offers an accessible technical solution to address structure-function hypotheses for virtually any RNA, regardless of its abundance. results development of genome-wide in vivo rnA structure probing with mutational profiling For DMS-MaPseq, we treated cells with a high concentration of DMS to increase the number of modifications detected per fragment, modifying approximately 1 in 50 nucleotides. We compared data produced at this DMS concentration (5% v/v) to previously validated concentrations 4 , and we observed excellent correlation of the RNA structure signal both globally and for each nucleotide in the yeast 18S rRNA (Supplementary Fig. 1 ; R = 0.94 and R = 0.98, respectively). For applications that aim to use even higher DMS levels, it will be important to do a similar analysis to evaluate whether RNA structures are perturbed with increasing DMS concentrations. After DMS treatment and total RNA extraction, random fragmentation with Zn 2+ , and the removal of ribosomal RNA, we did a broad size selection, ligated a 3′ adaptor, and reverse transcribed under conditions in which chemically modified bases were encoded as mutations in the cDNA (Fig. 1) . Consequently, multiple modifications can be observed on a single cDNA fragment, providing an essential framework for future applications of single-molecule RNA structure determination.
The accuracy of DMS-MaPseq depends critically on reverse transcription conditions that optimize the detection of DMS modifications while retaining high fidelity and processivity during cDNA synthesis. The TGIRT enzyme was recently adapted with these latter priorities in mind and notably produces mismatches at endogenous m 1 A and m 3 C tRNA residues-the exact methylation profiles of a DMS modification 18, 19 . Additionally, Superscript II with Mn 2+ buffer (SSII-Mn 2+ ) has been used for the mutational read through of DMS and SHAPE modifications for abundant individual RNA species [14] [15] [16] . To compare the suitability of these two enzymes for our in vivo DMS-MaPseq approach, we prepared genome-wide yeast libraries with each. Encoding DMS modifications as mismatches inherently retains the singlenucleotide resolution of DMS while insertions or deletions (indels) suffer from positional ambiguity when aligned across a homopolymeric stretch. TGIRT does not produce a high number of indels (6%, Fig. 2a) . However, we found that nearly a third of DMS-induced mutations from SSII-Mn 2+ reverse transcription were insertions or deletions. Next, we used two endogenous m 1 A modifications on the yeast 25S rRNA as internal controls for DMS lesion detection. The frequency of mismatches at these residues across TGIRT replicate experiments revealed m 1 A detection at 85% and 48% average frequency, placing a lower bound on the fraction of these endogenous modifications. SSII-Mn 2+ yielded average detection frequencies of only 53% and 1.4% at the same modified residues (Fig. 2b) . This tendency of SSII-Mn 2+ to under-report the DMS modification signal in a context-dependent manner could severely undermine data quality.
A valuable measure for the signal-to-noise ratio in DMS data is the enrichment of signal on adenines and cytosines 4 ( Supplementary Fig. 2a ). When the same source of DMS-modified RNA was reverse transcribed using either TGIRT or SSII-Mn 2+ , we observed a far greater fraction of mismatches on A-Cs using TGIRT (TGIRT, 93.5%; SSII-Mn 2+ , 84%) (Fig. 2c) . This high A-C signal in TGIRT data also exceeds that of our previously published DMS-seq strategy based on cDNA truncation, and there are notable differences in the relative contributions of A-Cs 4 . Analysis of the mismatch nucleotide bias in DMS-seq reveals that 54% of mismatches occur on cytosines in a DMS-dependent manner, suggesting that truncation at cytosines is not robust 14 ( Supplementary Fig. 2b,c) . Notably, the signal on adenines is lower with SSII-Mn 2+ than with the other techniques, which suggests an underlying failure of SSII-Mn 2+ to robustly encode m 1 A modifications consistent with the low signal detection on the endogenous rRNA residues.
Both TGIRT and SSII-Mn 2+ produce excellent signal at unpaired A-C residues in the yeast RPS28B positive-control structure, but the SSII-Mn 2+ data reveal high background signal on certain G-U residues, suggesting a propensity for nonrandom errors in cDNA synthesis. This higher background error for SSII-Mn 2+ is also reflected in the genome-wide frequency of mutations and indels on matched untreated and DMS-treated RNA (Supplementary Fig. 2d ), which is consistent with the historical use of Mn 2+ buffer in deliberate mutagenesis during oligonucleotide synthesis 20 . Other RNA structure methods have subtracted background signal on a nucleotide-by-nucleotide basis 15 ; however, we see an increase in noise after applying a background correction to the RPS28B positive-control structure 21 ( Fig. 2d and Supplementary Fig. 3a-d) . Global investigation reveals a poor correlation of background signal for both TGIRT and SSII-Mn 2+ untreated replicates, suggesting that background signal is variable and stochastic ( Supplementary Fig. 3e,f) . Thus, a key advantage of DMS-MaPseq is the ratiometric nature of the data (i.e., in a population-level analysis, the rate of modification at each position is equal to the ratio of mutated reads to total reads; Fig. 1 ). Untreated or denatured DMS-MaPseq controls may still be useful in the discovery of endogenous mRNA modifications encoded during reverse transcription 19 , uncharacterized single-nucleotide polymorphisms, or as a negative control, but it is not a necessary component for single-nucleotide RNA structure calculations. We used replicates to assess the reproducibility of the RNA structure signal across yeast transcriptome regions as measured by r value and the Gini index difference, an established RNA structure metric to assess the evenness of the data distribution 4 ( Fig. 2e) . This analysis revealed a stronger reproducibility between data generated by TGIRT than by SSII-Mn 2+ , consistent with our observations of high background noise in the latter approach. Because of the high DMS signal and low background error observed across many quality control metrics, we chose the TGIRT enzyme for all further DMS-MaPseq experimentation and method development.
Global analysis of dms-maPseq data
When DMS lesions are detected by truncation, only the most 3′ DMS modification on an RNA fragment will be detected. For this reason, DMS treatment conditions must be carefully titrated to avoid improper hit kinetics and 5′ signal decay 22 . This effect is illustrated by the lack of DMS-seq signal immediately 5′ of an endogenous m 1 A residue in denatured yeast 25S rRNA (Fig. 3a) . This drop off does not occur with DMS-MaPseq data, confirming that the TGIRT enzyme can encode multiple DMS lesions in a short sequence space. Additionally, negative-control bases in the yeast rRNA fall overwhelmingly into the lowest bin of reactivity in DMS-MaPseq data, confirming low background noise relative to previous DMS-seq data 4 (Fig. 3b) .
We also collected a genome-wide in vivo DMS-MaPseq data set from human embryonic kidney (HEK) 293T cells, and we confirmed the agreement of our data with the XBP1 positivecontrol structure 23 ( Supplementary Fig. 4 ). Often, a region of high GC content is considered a candidate region for RNA folding owing to the high stability of G-C pairings, so we investigated this relationship across human transcriptome regions, plotting GC content against the Gini index from DMS-MaPseq (Fig. 3c) . A small correlation (R = 0.32) exists, but overall, coding regions have lower GC content, and their RNA appears less structured, as we demonstrated previously 4 . However, the lack of structure is more pronounced than expected by GC content alone, and noncoding RNA regions are more structured than coding DNA sequence (CDS) regions of comparable GC content. Interestingly, the biggest outliers are small nucleolar RNAs (snoRNAs) and small nuclear RNAs (snRNAs), which have a low GC content but are highly structured.
dms-maPseq for specific or low-abundance rnA targets Low-abundance mRNAs do not receive sufficient sequencing coverage in genome-wide experiments to enable robust conclusions about their structure. Plotting the cumulative r value distribution for mRNA regions between in vivo DMS-MaPseq replicates in yeast reveals that an average mismatch coverage depth of greater than 20× greatly improves data reproducibility (Fig. 4a) . However, for genome-wide HEK 293T DMS-MaPseq data, only a limited fraction of genes pass this 20× coverage threshold (Fig. 4b) . Even when extrapolated to an exorbitant sequencing depth of 1 billion uniquely mapped reads, many human genes (78%) have insufficient coverage. To probe the in vivo structure of low-abundance mRNAs, we developed and validated a simple targeted RT-PCR implementation of DMS-MaPseq (Fig. 4c) . Targeted DMSMaPseq begins with the in vivo modification of RNA, followed by total RNA extraction, DNase treatment, and rRNA depletion. Then, we reverse-transcribe using the TGIRT enzyme and target-specific primers (primers can be used in combination to amplify multiple RNA species in a single reaction). Directly after cDNA synthesis, target-specific PCR primers amplify the RNA region of interest, and this is followed by NexteraXT tagmentation and sequencing.
To assess data quality from this targeted approach, we examined the structure signal for known RNA structures. We plotted a receiver operating characteristic (ROC) curve to assess the concordance of 18S rRNA DMS-MaPseq data with the published yeast crystal structure model 24 and observed an excellent agreement with data from both our genome-wide and targeted approach ( Fig. 4d and Supplementary Fig. 5a ). We also assessed whether the targeted DMS-MaPseq data supported positive-control mRNA structure models, and we observed excellent agreement with the yeast HAC1 and RPS28B structures 21, 25 (Fig. 4e,f) as well as with the human XBP1 and MSRB1 structures 23, 26 ( Supplementary  Fig. 5b-e) . Finally, we observed no signal drop-off in our amplified regions until the primer-binding region, and we observed a low level of background signal (Supplementary Fig. 6 ).
To reduce PCR amplification biases for quantitative applications or low-input material, we also developed a variation of targeted DMS-MaPseq that tags each RNA molecule with a unique molecular index (UMI) on the RT primer ( Supplementary Fig. 7a and Supplementary Table 1) . Unique reads can then be isolated easily based on their specific UMI and DMS mutation profiles. The SFT2 and ASH1 yeast mRNAs are weakly expressed and host functional RNA structures in their 5′ and 3′ UTRs, respectively, serving as positive controls for DMS signal detection using a UMI. Indeed, both controls show DMS modification profiles consistent with the known secondary structure models 4, 27 ( Supplementary  Fig. 7b,c) . Irrespective of their uniqueness, these data are in excellent agreement when processed, which suggests that a UMI may not be necessary for amplification of transcripts of comparable abundance. Given the limitations regarding the size of RNA region assayed with this UMI approach and the expense of longer sequencing reads, choosing between the targeted versions of DMS-MaPseq depends on the region size, target abundance, and quantitative demands of an experiment.
dms-maPseq for Drosophila melanogaster ovaries
With their dramatic developmental changes independent of transcription and mRNA degradation, D. melanogaster oocytes provide a premier system for studying mRNA localization and translational control. Many mRNAs are localized during oogenesis 28 , and while these localization mechanisms are poorly understood globally, RNA structure has been shown to be involved [29] [30] [31] . Here, we apply targeted DMS-MaPseq to D. melanogaster ovaries, which yields excellent structure data at two DMS treatment levels consistent with the oskar and gurken mRNA structures responsible for localization 31, 32 (Fig. 5a,b and Supplementary Fig. 8 ). This is the first example of RNA structure probing in an animal tissue and marks a key step forward in investigating the role of RNA structure in mRNA localization in this model system.
A highly structured region influences noncanonical translation initiation
We recently discovered that translation of the mammalian FXR2 (Fragile X Mental Retardation, Autosomal Homolog 2) gene initiates predominantly at a GUG codon 33 . On account of the extreme GC content (80%) of the first exon of FXR2, we hypothesized a stable RNA structure may contribute to the non-canonical initiation. We used in vitro DMS-MaPseq data to develop a secondary structure model with RNAfold 34 . This revealed two highly stable putative structures flanking the GUG initiation codon (Fig. 5c,   Supplementary Fig. 9 ; free energy < -31 kcal/mol), with some ambiguity across certain regions depending on the thresholds used to impose folding constraints (see alternative structure model, Supplementary Fig. 10a ). We mutated these putative FXR2 structures to perturb the majority of base-pairing interactions in both models and tested their effects within a reporter construct, revealing a drop in protein levels upon mutating either structure ( Supplementary Fig. 10b-d and Supplementary Table 2) . Compensatory mutations, designed to optimize the restoration of our predicted RNA structures, restored eGFP levels and thus implicated the structure itself as a functional modulator of translation initiation for FXR2. In addition to the compensatory mutations, the in vivo structure signal supports this model ( Supplementary Fig. 9c-e) .
structure probing of rnAs in multiple conformations
In the complex environment of the cell, the structure of an RNA molecule may vary based on its current state, such as maturation, translation, protein binding, and degradation. In the case of structural heterogeneity from a ribosnitch (i.e., a single-nucleotide polymorphism that yields a local RNA structure rearrangement), the interpretation of in vitro RNA folding status differs greatly when DMS-MaPseq data from the two human MRPS21 ribosnitch alleles 35 are analyzed together or separately. Allele-specific analysis of the data reveals two distinct and mutually exclusive structures, which are not detectable from the combined allele analysis (Fig. 6a) . This example illustrates the complexity of analyzing structurally heterogeneous regions and a simple resolution using DMSMaPseq to separate specific RNA subpopulations by allele.
Of particular interest regarding structural heterogeneity are isoform-specific RNA structures. Structure differences have been proposed between pre-mRNAs and their mature translated counterparts, such as RNA structures that influence splice-site selection 36 or affect translation 37, 38 . We used intron-or exonspecific RT primers to separately amplify each isoform of two yeast ribosomal protein genes using targeted DMS-MaPseq. The RNA structure signal in the common exon1 sequence between the RPL14A and RPL31B pre-mRNAs and their respective mature counterparts reveals surprisingly little structure difference between isoforms (Fig. 6b, Supplementary Figs. 11 and 12) . These mRNAs are highly translated, but their exon1 structure is similar to that of the untranslated pre-mRNA, suggesting that local RNA structure rapidly refolds after translation. While we focus here on a limited number of messages, this approach broadly enables the analysis of different RNA isoforms.
discussion
Here we establish DMS-MaPseq as a robust and simple tool suitable for the quantitative analysis of RNA secondary structure in vivo by improving the inherent quality of the structure data, enabling qualitatively new types of structure to be gathered, and greatly expanding the repertoire of RNAs that can be analyzed. Future applications include in vivo single-molecule analyses of the co-occurrence of DMS modifications to identify heterogeneous RNA structure subpopulations (e.g., ribosnitches 35 ) empirically. Additionally, DMS-MaPseq allows the selective amplification of RNA targets, including pre-mRNAs or differentially spliced isoforms. Together, these advances drastically expand the range of experimentally accessible RNA species for structural analysis, enabling a wide range of future studies. In theory, our in vivo MaP approach with TGIRT could also be used for SHAPE, which would be a valuable and complementary approach. However, the bulky nature of the best characterized and validated in vivo SHAPE chemical, NAI-N 3 (ref. 10), may prove challenging. Finally, DMS-MaPseq could be combined with the analysis of endogenous mRNA modifications, including the sequencingbased mapping of pseudouridines or m 6 A methylation [39] [40] [41] [42] . These endogenous modifications occur on only a subset of their RNA targets. Combined with the single-molecule aspects of DMSMaPseq, it would be possible to evaluate how such endogenous RNA modification affects structure within a single experiment. It is the versatility of DMS-MaPseq that makes it a transformative tool for in vivo RNA structure probing, allowing for more comprehensive investigations into the biological relevance of RNA structures than ever before. methods Methods and any associated references are available in the online version of the paper.
Accession codes. Raw and processed data are available at NCBI Gene Expression Omnibus, accession number GSE84537. 
online methods
Step-by-step protocols for target-specific and genome-wide DMS-MaPseq are available as Supplementary Protocols 1 and 2 (and refs. 43 and 44).
Media and growth conditions. Yeast strain BY4741 was grown in YPD medium at 30 °C. Saturated cultures were diluted to OD 600 of ~0.09 and grown to a final OD 600 of 0.5-0.7 at the time of DMS treatment. HEK 293T cells were grown in DMEM medium with high glucose, supplemented with glutamine, pyruvate, nonessential amino acids, and 10% fetal bovine serum (FBS); and cells were treated with DMS at ~80% confluence.
Dimethyl sulfate (DMS) modification.
For in vivo DMS modification in yeast, 15 ml of exponentially growing yeast was incubated with 750 µl DMS (Sigma) for 4 min at 30 °C. DMS was quenched by adding a 30 ml stop solution comprised of 30% beta-mercaptoethanol (from a 14.2 M stock) and 50% isoamyl alcohol, after which cells were quickly put on ice, collected by centrifugation at 3,500 × g at 4 °C for 4 min, and washed with 10 ml 30% BME solution. Cells were then resuspended in 0.6 ml total RNA lysis buffer (6 mM EDTA, 45 mM NaOAc pH 5.5), and total RNA was purified with hot acid phenol (Ambion) and EtOH precipitation. Ribosomal RNA was depleted using RiboZero (Epicentre), either directly after RNA extraction or postligation in the genome-wide library preparation. Denatured RNA structure samples were treated as in DMS-seq 4 . For HEK 293T cells, 15 cm 45 plates with 15 ml of media were treated with the addition of 300 µl DMS and incubation at 37 °C for 4-5 min. Media with DMS was decanted, and plates were washed twice in 30% BME (v/v). Cells were resuspended in Trizol, and RNA was isolated according to the manufacturer protocol. For D. melanogaster oocytes, we dissected ovaries from ~100 flies (OreR strain) in 250 µl 1× PBS. We added 250 µl DMS for 5 min at 26 °C with shaking at 500 r.p.m. To stop the reaction, we added 1 ml of 30% BME (v/v) and transferred the oocytes to a sieve, where they were washed three times in 30% BME and two times with sterile water. Finally, the ovaries were collected and resuspended in 1mL of Trizol and 10 µl BME, and total RNA was extracted.
Library generation and genome-wide DMS-MaPseq. Sequencing libraries were prepared with a modified version of the protocol used for DMS-seq 4 . Specifically, 10 µg of DMS-treated total RNA was denatured for 2 min at 95 °C then fragmented at 95 °C for 2 min in 1× RNA Fragmentation Reagent (Zn 2+ based, Ambion). Note that this is an increase in starting material over the 1-3 µg used in our previous DMS-seq approach (REF). The reaction was stopped with 1× Stop Solution (Ambion) and quickly placed on ice. The fragmented RNA was run on a 6% Tris Borate Urea (TBU) polyacrylamide gel for 45 min at 150 V. A blue light (Invitrogen) was used for gel imaging, and RNA fragments of 100-170 nt in size were excised, depleting small ncRNA contaminants of <100 nt (tRNAs, snoRNAs). Gel extraction was performed by crushing the purified gel piece and incubating in 300 µl 300 mM NaCl at 70 °C for 10 min with vigorous shaking. The RNA was then precipitated by adding 2 µl GlycoBlue (Invitrogen) and 3× volume (900 µl) 100% EtOH, incubating on dry ice for 20 min and spinning at 20,000 × g for 45 min at 4 °C. The samples were then resuspended in 7 µl 1× CutSmart buffer (NEB), and the 3′ phosphate groups left after random fragmentation were resolved by adding 1.5 µl rSAP (NEB), 1 µl of SUPERase Inhibitor (Ambion), and incubating at 37 °C for 1 h. After heat inactivation of the phosphatase at 65 °C for 5 min, the samples were then directly ligated to 25 pmol of miRNA cloning linker-2 (IDT) by adding 2 µl T4 RNA ligase2, truncated K227Q (NEB), 1 µl 0.1 M DTT, 6.5 µl 50% PEG, 1 µl 10× T4 RNL2 buffer, and incubating for 2 h at 25 °C. Reactions were purified by EtOH precipitation (as above), and excess linker was degraded for 1 h at 30 °C in a 20 µL reaction of 1× RecJ buffer, 1 µl SUPERase Inhibitor, 1 µl 5′ Deadenylase (Epicentre), and 1 µl RecJ exonuclease (Epicentre). Ribosomal RNA was depleted using RiboZero (Epicentre) with a final incubation of 5 min at 40 °C, instead of 50 °C as recommended in the commercial protocol, and purified by EtOH precipitation. Reverse transcription was performed in a 10 µl volume with 1 pmol oCJ200-link2. To begin, a mixture of RNA-primer-buffer was incubated at 80 °C for 2 min to denature the template, then it was returned to ice for the addition of SUPERase Inhibitor (Ambion), DTT, dNTPs, and RT enzyme to generate the final reaction conditions. For reverse transcription using superscript II with Mn 2+ buffer, we followed the exact published reactions conditions for mutational profiling 14 (0.5 mM dNTPs, 50 mM Tris-HCl pH 8.0, 75 mM KCl, 6 mM MnCl 2 , and 10 mM DTT) and allowed the reaction to proceed for 2-3 h at 42 °C with 100 U of superscript II (Invitrogen). Because TGIRT may pause at modification sites, this long incubation time facilitates readthrough of multiple modifications per RNA fragment. For the TGIRT reverse transcription, a 5 min incubation at room temperature followed the initial denaturation, and the RT reaction proceeded for 1.5 h at 57 °C with 100 U TGIRT-III enzyme (InGex) and the following reaction conditions: 1 mM dNTPs, 5 mM freshly prepared DTT (Sigma-Aldrich), 10 U SUPERase Inhibitor, 50 mM Tri-HCl pH 8.3, 75 mM KCl, and 3 mM MgCl 2 . After reverse transcription, 1 µl of 5 M NaOH was added and the reaction incubated for 3 min at 95 °C to degrade the RNA, followed by EtOH precipitation and gel purification to remove excess RT primer. Finally, cDNAs were circularized using CircLigase (Epicentre), and Illumina sequencing adapters and indexes were introduced by 9-13 cycles of PCR using Phusion HF Polymerase (NEB), oNTI231, and indexing primers with TruSeq 6 bp indices. Libraries were sequenced with oNTI202 in 50 nt single-end reads on the HiSeq4000 (Illumina). See primer sequences in Supplementary Table 1. Library generation and targeted DMS-MaPseq. After in vivo DMS treatment and total RNA extraction, 5 µg of total RNA was DNase-treated for 30 min at 37 °C in 1× TURBO DNase buffer with 1 µl TURBO DNase enzyme (Thermo Fisher Scientific). Reactions were desalted using RNA Clean & Concentrator-5 columns (Zymo Research), and rRNA was depleted using RiboZero (Epicentre) or RNase H for D. melanogaster and HEK 293T samples; RNase H treatment was implemented with slight modifications to the published protocol 46 . For the RNase H protocol, briefly, 5 µg of total RNA was depleted of small RNA species with a Zymo RNA Clean & Concentrator-5 column, retaining RNA >200 nt per manufacturer instructions. RNase H subtraction was performed by adding 5 µg of published subtraction oligos 46 in a total volume of 30 µl in 1× hybridization buffer (200 mM NaCl, 100 mM Tris pH 7.5). The mixture was incubated at 68 °C for 1 min, and the temperature was ramped down at a rate of 1 °C/min to 45 °C. MgCl 2 was added to a 10 mM final concentration, and 3 µl of Hybridase Thermostable RNase H (Epicentre) was added, followed by a 30 min incubation at 45 °C. The reaction was again purified by Zymo RNA Clean & Concentrator-5 column to deplete small RNA species, followed by treatment with DNaseI (Ambion) per manufacturer instructions and a final column clean up to remove excess RNase H subtraction oligos.
20-100 ng of RNA was used for reverse transcription with 100 U TGIRT-III (InGex) for 2 h at 57 °C in the same TGIRT reaction conditions as those described above. We used 5-10 pmol of each gene-specific RT primer and successfully pooled up to six different RT primers in one reaction, using no more than 35 pmol total. DTT was prepared from powder directly before reverse transcription, and we omitted the denaturation step before reverse transcription on account of low-level fragmentation of DMS-treated RNA at high temperatures. After moving the reaction to ice, 1 µl RNase H (Enzymatics, 5 U/µl) was added, and RNA-DNA hybrids were degraded at 37 °C for 20 min to release the cDNA. We used RNase H at this step for convenience-NaOH hydrolysis as used in the genome-wide protocol also works well at this step. cDNA was purified using the ssDNA protocol for DNA Clean & Concentrator-5 columns (Zymo Research). We used the Advantage HF 2 PCR kit (Clontech) with highfidelity conditions for two-step PCR amplification, using 1/12 of the purified RT reaction and gene-specific primers targeting a single template with a target amplicon size of 300-600 nt for low-abundance RNA targets. When possible, we designed our gene-specific RT primers close to the PCR amplicon of interest, and in many cases we used the RT primer as the reverse primer in our PCR reactions. High-abundance RNAs, such as the yeast 18S rRNA, can be amplified in a single 1.8 kb amplicon. Because of the high GC content of the FXR2 template, we used 200 mM NaCl instead of 75 mM KCl in the RT reaction buffer and the Advantage GC 2 PCR Kit (Clontech) for its amplification. The PCR program begins with 10 cycles at a 65 °C annealing temperature to promote specificity, followed by 20-25 cycles at a 57 °C annealing temperature. PCR bands were gel purified on a nondenaturing 8% TBE polyacrylamide gel (Invitrogen) and crushed, extracted, and EtOH precipitated as described above. NexteraXT (Illumina) was used to fragment and prepare amplicons (1 ng) for sequencing. Tagmented amplicons were barcoded and amplified using 12 cycles of PCR, and barcoded libraries were cleaned using 1.5× (v/v) PCRClean beads (Aline Biosciences). Libraries were quantified using the Fragment Analyzer (Advanced Analytical) and subjected to a final quantification by qPCR before sequencing by 50 bp single-end reads on the HiSeq4000 (Illumina).
For the UMI-based RT-PCR, reverse transcriptase primers were designed with a random 10 nt barcode, labeling each cDNA with a unique molecular index. Gene-specific variations of oMZ282 were used in the reverse transcription reaction described above, followed by Advantage HF 2 PCR with gene-specific variants of primers oMZ282 and oMZ283. Amplicons were purified by polyacrylamide gel and extracted as described above, and a second round of PCR was done with 20-25 cycles to add Illumina adaptors and indices for sequencing (oMZ284 and indexing primers). Libraries were constructed so the UMI was sequenced first using custom Read1 sequencing primer oNTI202. We used the standard Illumina Read2 primer, and sequencing was done via MiSeq v2 2 × 150 (Illumina). See primer sequences in Supplementary Table 1. Ribosnitch RNA preparation. dsDNA corresponding to the human MRPS21 sequences shown below were in vitro transcribed, mixed, and folded by denaturing at 95 °C followed by a brief incubation at 37 °C in 350 mM sodium cacodylate buffer and 6 mM MgCl 2 . 10% DMS (v/v) was added, and the sample was incubated for 10 min at 37 °C. The reaction was stopped by placing on ice and adding BME to 30% final volume. The RNA was then purified by RNA Clean & Concentrator-5 column (Zymo), and the small RNA fraction was collected and prepared for sequencing as described in the genome-wide strategy above.
MRPS21 A allele: 5′-TGCTGCCATCTCTTTTCTTCTCTATG CGAGGATTTGGACTGGCAGTG-3; MRPS21 C allele: 5′-ATC TCTTTTCTTCTCTCTGCGAGGATTTGGACTGGCAGTGAG AATAAGAGACAA-3′.
Sequencing alignment and analysis. Raw fastq files were stripped of linker sequences and filtered for quality using the FASTX-Toolkit Clipper and Quality Filter functions, respectively, requiring that 80% of sequenced bases have a quality score >25 (http://hannonlab.cshl.edu/fastx_toolkit/). Reads were aligned using Tophat v2.1.0 with bowtie2 with the following settings for a 50 nt sequencing run:-no-novel-juncs -N 5-read-gap-length 7-read-edit-dist 7-max-insertion-length 5-max-deletion-length 5 -g 3. All nonuniquely aligned reads were then removed. Sequencing data was aligned against the Saccharomyces cerevisiae assembly R64 (UCSC, sacCer3) downloaded from the Saccharomyces Genome Database on February 8, 2011 (SGD, http://www.yeastgenome. org) or against the longest human RefSeq isoforms (hg19). Despite template-switching capabilities of the TGIRT enzyme, we did not detect a substantial number of chimeric reads in our data and did not include a processing step beyond alignment to remove these. On account of empirically determined mutation enrichment from nontemplate addition and Nextera XT transposase insertion, we trimmed 2, 5, and 7 nt from the 5′ end of each read for TGIRT-, SSII-Mn 2+ -, and NexteraXT-generated libraries, respectively. Mismatches located within 3 nt of an indel were also discarded for future analysis. The ratiometric DMS signal was calculated for each nucleotide as number of mismatches/sequencing depth.
Target-specific sequencing data prepared with NexteraXT were combined across both strand alignments, because of lack of strandedness after tagmentation. Transposase insertion is subject to primary sequence biases in transposase insertion; thus it is possible (although rare) to have amplicon regions that are poorly sampled and result in false-positive bases with high ratiometric reactivity due to poor sequencing depth. After linker stripping with a length requirement for reads >100 nt from a 2 × 150 nt MiSeq run, target-specific sequencing data prepared with the UMI was collapsed to unique reads using FASTX-Collapser. Unique reads are, therefore, the combination of a unique molecular index and internal DMS-induced modifications, which add sequence diversity beyond the 10 bp UMI.
Genome-wide yeast DMS-MaPseq data was collected and sequenced with two biological replicates for each SSII-Mn 2+ and TGIRT, untreated and in vivo DMS-treated libraries. For each library variation, we collected a combined total of 90 to 200 million uniquely mapped reads between yeast replicates and 200 million for HEK 293T cells. Note that we sequenced to a similar depth for a genome-wide DMS-MaPseq experiment as we did for our previously published genome-wide DMS-seq method 43 .
HEK 293T Gini index calculations. UTR and coding regions were defined by RefSeq coordinates, and we analyzed 50 nt windows beginning at the annotated transcription start site. After requiring a minimum number of 100 total reads at As or Cs and >20× mismatch coverage for each window, we also discarded any windows with evidence for endogenous modifications (>15% mismatch rate). The Gini index was calculated only for A and C bases, as done previously 4 .
Minimum average coverage calculation. Using 100 nt transcriptome windows, we chose the window with the highest total sequence coverage as representative coverage for the gene. We counted the fraction of genes from the hg19 RefSeq annotation that had an average mismatch coverage >120 mismatches at sequencing depths of 50, 100, and 200 million uniquely mapped reads. We extrapolated the data for 1 billion reads.
Computing the ROC curve for ribosomal RNA. This analysis was completed as previously described, using the yeast ribosome crystal structure 24 and the same considerations for solvent accessibility and removal of outliers by 90% Winsorization 4 .
Secondary structure models. Novel secondary structure models were generated using constraints derived from DMS-MaPseq data using RNAfold 34 . For FXR2, the sequence corresponding to nucleotides 1-450, which comprise the 5′ UTR and first exon, were folded in RNAfold. Adenine and cytosine bases with an in vitro ratiometric signal greater than the selected threshold (which varied between 0.03 and 0.06, as specified in the relevant figure legends) were required to be unpaired. Depending on the threshold used, small differences exist in the predicted structure; however, the 0.04 constraint threshold appears to produce the best fitting model for our experimental data. Because of the high GC content of the FXR2 region (80% GC) and the necessity of using a low-fidelity GC polymerase for these experiments, an untreated control was used to mask ten positions with reactivity above background. DMS-MaPseq reactivities were overlaid on structure models using VARNA (http://varna.lri.fr/) 47 .
Cloning and transfection experiments. The plasmid construct in Supplementary Figure 5 was derived from the ∆ATG FXR2 exon1-eGFP-IRES-mCherry plasmid described in Fields et al. 33 .
A gBlock (IDT) was ordered containing a 43bp FXR2-3×FLAG-T2A-AgeI-eGFP (40-bp fragment) for HiFi assembly (NEB) into the linearized plasmid backbone. This wild-type plasmid was used as the PCR template for FXR2 mutations, which were designed as overhangs on primers against the relevant portion of the FXR2 exon1 sequence, resulting in 5′ and 3′ fragments with overlapping mutated regions for HiFi assembly into the linearized wild-type backbone. Successful amplification of fragments was confirmed by running a fraction on an agarose gel, and the remainder of the fragments was purified using DNA Clean & Concentrator-5 columns (Zymo) or, in the case of contaminating PCR bands, purified via agarose gel and MinElute gel extraction (Qiagen). Common cloning primers for FXR2 amplification from the plasmid are 5′-CTCACTCGGCGCGCCAGTC-3′ (5′ FXR2 fragment, forward) and 5′-TATAGTCCCCGTCGTGATCCTTGTA-3′ (3′ FXR2 fragment, reverse). Inserts in all analyzed constructs were confirmed by Sanger sequencing (Molecular Cloning Laboratories). Plasmids are listed in Supplementary Table 2 .
For fluorescence measurements, HEK 293T cells were grown as described and transfected with plasmids using TransIT-LT1 (Mirus) 2 d before data collection. eGFP and mCherry fluorescence were quantified using an LSR-II flow cytometer (BD Biosciences). Two plasmids for each type of mutation were assayed for fluorescence, serving as biological duplicates.
